Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct;57(10):1573-1580.
doi: 10.1038/s41409-022-01754-y. Epub 2022 Jul 15.

Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial

Yingling Zu  1   2 , Zhen Li  1 , Ruirui Gui  1 , Yanyan Liu  1 , Yanli Zhang  1 , Fengkuan Yu  1 , Huifang Zhao  1 , Yuewen Fu  1 , Xinrong Zhan  3 , Zhongliang Wang  3 , Pengtao Xing  3 , Xianjing Wang  4 , Huili Wang  4 , Jian Zhou  5 , Yongping Song  6   7
Affiliations
Randomized Controlled Trial

Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial

Yingling Zu et al. Bone Marrow Transplant. 2022 Oct.

Abstract

The most widely used regimens of graft-versus-host disease (GVHD) prophylaxis in HLA-matched unrelated donor peripheral blood stem cell transplantation (MUD-PBSCT) are based on anti-thymocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy). To improve the efficiency of GVHD prophylaxis, a novel regimen, composed of low-dose PTCy (20 mg/kg on day +3 and +4) and low-dose ATG (6 mg/kg), was evaluted in patients with hematological malignancies ungoing 10/10 HLA MUD-PBSCT in first remission (CR1). In our prospective, multicenter study, 104 patients were randomly assigned one-to-one to low-dose PTCy-ATG (n = 53) or standard-dose ATG (10 mg/kg, n = 51). Both the cumulative incidences (CIs) of grade II-IV acute GVHD (aGVHD) and chronic GVHD (cGVHD) at 2 years in low-dose PTCy-ATG cohort were significantly reduced (24.5% vs. 47.1%; P = 0.017; 14.1% vs. 33.3%; P = 0.013). The CI of non-relapse-mortality (NRM) was much lower (13.2% vs. 34.5%; P = 0.049) and GVHD-free, relapse-free survival (GRFS) was significantly improved at 2 years in low-dose PTCy-ATG arm (67.3% vs 42.3%; P = 0.032). The low-dose PTCy-ATG based GVHD prophylaxis is a promising strategy for patients in CR1 after 10/10 HLA MUD-PBSCT.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Flowchart of the study participants.
PTCy post-transplant cyclophosphamide, ATG anti-thymocyte globulin.
Fig. 2
Fig. 2. Cumulative incidences (CIs) of graft-versus-host-disease (GVHD) between low-dose post-transplant cyclophosphamide (PTCy) combined with low-dose anti-thymocyte globulin (ATG) and standard-dose ATG cohorts.
a The CI of grade II-IV acute GVHD (aGVHD); b The CI of grade III-IV aGVHD; c The 2-year CI of chronic GVHD (cGVHD); d The 2-year CI of moderate to severe cGVHD.
Fig. 3
Fig. 3. Clinical outcomes after matched unrelated donor peripheral blood stem cell transplantation (MUD-PBSCT) between low-dose post-transplant cyclophosphamide (PTCy) combined with low-dose anti-thymocyte globulin (ATG) and standard-dose ATG cohorts.
a The 2-year CI of relapse; b The 2-year CI of non-relapse-mortality (NRM); c The 2-year probability of overall survival (OS); d The 2-year probability of disease-free survival (DFS); e The 2-year CI of GVHD-free, relapse-free survival (GRFS).
See this image and copyright information in PMC

References

    1. Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, et al. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4:983–92. doi: 10.1182/bloodadvances.2019001126. - DOI - PMC - PubMed
    1. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:2230–9. doi: 10.1200/jco.2010.33.7212. - DOI - PMC - PubMed
    1. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–73. doi: 10.1016/s1470-2045(15)00462-3. - DOI - PubMed
    1. Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4:e293–e301. doi: 10.1016/s2352-3026(17)30081-9. - DOI - PubMed
    1. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157–e167. doi: 10.1016/s2352-3026(19)30256-x. - DOI - PubMed

Publication types

MeSH terms